keyword
MENU ▼
Read by QxMD icon Read
search

Paricalcitol

keyword
https://www.readbyqxmd.com/read/29142954/asymmetric-dimethylarginine-adma-levels-are-lower-in-hemodialysis-patients%C3%A2-treated-with-paricalcitol
#1
Elena Oliva-Damaso, Nestor Oliva-Damaso, Francisco Rodriguez-Esparragon, Juan Payan, Alberto Marañes, Yanet Parodis, Lopez Eduardo Baamonde-Laborda, Nicanor Vega Diaz, Jose Carlos Rodriguez-Perez
Introduction: Chronic kidney disease is a major public health problem. In the last decade, it has been shown that the early stages of chronic kidney disease are associated with an inflammatory condition involving an increased risk of cardiovascular morbidity and long-term mortality. In patients with chronic kidney disease and more specifically those on hemodialysis, cardiovascular events are the most common cause of death. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase and may be an independent risk factor for endothelial dysfunction and cardiovascular disease...
March 2017: KI Reports
https://www.readbyqxmd.com/read/29104158/moderate-salt-restriction-with-or-without-paricalcitol-in-type-2-diabetes-and-losartan-resistant-macroalbuminuria-proceed-a-randomised-double-blind-placebo-controlled-crossover-trial
#2
Aneliya Parvanova, Matias Trillini, Manuel A Podestà, Ilian Petrov Iliev, Barbara Ruggiero, Manuela Abbate, Annalisa Perna, Francesco Peraro, Olimpia Diadei, Nadia Rubis, Flavio Gaspari, Fabiola Carrara, Nadia Stucchi, Antonio Belviso, Antonio C Bossi, Roberto Trevisan, Giuseppe Remuzzi, Martin de Borst, Piero Ruggenenti
BACKGROUND: Macroalbuminuria predicts renal and cardiovascular events in patients with type 2 diabetes. We aimed to assess the albuminuria-lowering effects of salt restriction, paricalcitol therapy, or both, in this population. METHODS: In this randomised, double-blind, placebo-controlled, crossover trial, we recruited adult patients with type 2 diabetes from six diabetology outpatient clinics in northern Italy, with 24 h albuminuria of more than 300 mg despite 100 mg per day losartan therapy, blood pressure of less than 140/90 mm Hg, serum creatinine concentration of less than 2 mg/dL, stable renal function on stable renin-angiotensin system inhibitor therapy with a fixed dose of losartan, parathyroid hormone concentration of 20 pg/mL to <110 pg/mL, serum calcium concentration of less than 9·5 mg/dL, and serum phosphate concentration of less than 5 mg/dL, who had been more than 80% compliant with placebo treatment during a 1 month placebo run-in...
November 2, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29104157/paricalcitol-and-albuminuria-tread-carefully
#3
Beatriz Fernandez-Fernandez, Alberto Ortiz
No abstract text is available yet for this article.
November 2, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29067991/does-combination-of-paricalcitol-with-cinacalcet-in-secondary-hyperparathyroidism-in-hemodialysis-treatment-make-sense
#4
Jacek Zawierucha, Jolanta Małyszko, Jacek Małyszko, Tomasz Prystacki, Wojciech Marcinkowski, Teresa Dryl-Rydzyńska
INTRODUCTION    Secondary hyperparathyroidism (SHPT) is a common hormonal disorder associated with  chronic kidney disease (CKD). SHPT treatment should lead to reduction of parathormon concentration by calcimimetics or active vitamin D administration and calcium-phosphate metabolism stabilization. In the event of failure of conservative treatment complete or partial parathyroid resection should be considered.  OBJECTIVES    The aim of the study was assessement of beneficial effects of treatment with paricalcitol and cinacalcet simultaneously versus paricalcitol alone...
October 25, 2017: Polish Archives of Internal Medicine
https://www.readbyqxmd.com/read/29064176/calciphylaxis-after-parathyroidectomy
#5
Sathish Karmegam, Anupkumar Shetty
A 60-year-old African American man with end stage renal disease on hemodialysis (HD) for the past 2.5 years developed severe hyperparathyroidism. Other past medical history included atrial fibrillation, type II diabetes mellitus, hypertension, gout, pericardial effusion needing pericardial window, deep vein thrombosis, mitral insufficiency, and cardiomyopathy with implantable cardioversion device placement. His parathyroid hormone (PTH) level peaked at 4,191 pg/mL despite being on cinacalcet, sevelamer, and paricalcitol...
October 2017: Hemodialysis International
https://www.readbyqxmd.com/read/29038882/etelcalcetide-a-novel-calcimimetic-prevents-vascular-calcification-in-a-rat-model-of-renal-insufficiency-with-secondary-hyperparathyroidism
#6
Longchuan Yu, James E Tomlinson, Shawn T Alexander, Kelly Hensley, Chun-Ya Han, Denise Dwyer, Marina Stolina, Charles Dean, William G Goodman, William G Richards, Xiaodong Li
Etelcalcetide, a novel peptide agonist of the calcium-sensing receptor, prevents vascular calcification in a rat model of renal insufficiency with secondary hyperparathyroidism. Vascular calcification occurs frequently in patients with chronic kidney disease (CKD) and is a consequence of impaired mineral homeostasis and secondary hyperparathyroidism (SHPT). Etelcalcetide substantially lowers parathyroid hormone (PTH) and fibroblast growth factor-23 (FGF23) levels in SHPT patients on hemodialysis. This study compared the effects of etelcalcetide and paricalcitol on vascular calcification in rats with adenine-induced CKD and SHPT...
December 2017: Calcified Tissue International
https://www.readbyqxmd.com/read/28992684/paricalcitol-attenuates-indoxyl-sulfate-induced-apoptosis-through-the-inhibition-of-mapk-akt-and-nf-kb-activation-in-hk-2-cells
#7
Jung Sun Park, Hoon In Choi, Eun Hui Bae, Seong Kwon Ma, Soo Wan Kim
Background/Aims: Indoxyl sulfate (IS) is a uremic toxin and an important causative factor in the progression of chronic kidney disease. Recently, paricalcitol (19-nor-1,25-dihydroxyvitamin D2) was shown to exhibit protective effects in kidney injury. Here, we investigated the effects of paricalcitol treatment on IS-induced renal tubular injury. Methods: The fluorescent dye 2',7'-dichlorofluorescein diacetate was used to measure intracellular reactive oxygen species (ROS) following IS administration in human renal proximal tubular epithelial (HK-2) cells...
October 10, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/28976989/vitamin-d-and-methylarginines-in-chronic-kidney-disease-ckd
#8
RANDOMIZED CONTROLLED TRIAL
Claudia Torino, Patrizia Pizzini, Sebastiano Cutrupi, Rocco Tripepi, Giovanni Tripepi, Francesca Mallamaci, Carmine Zoccali
BACKGROUND: Vitamin D associates with the plasma concentration of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl arginine (ADMA) and cross-sectional studies in CKD patients treated with the vitamin D receptor activator paricalcitol show that plasma ADMA is substantially less than in those not receiving this drug. METHODS: In the frame of a randomized, double-blind, placebo controlled trial, the Paracalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY), we investigated whether vitamin D receptor activation by paricalcitol (2 μg/day x 12 weeks) affects the plasma concentration of ADMA and symmetric dimethyl arginine (SDMA) in 88 patients with stage 3 to 4 CKD...
2017: PloS One
https://www.readbyqxmd.com/read/28956807/long-term-therapy-outcomes-when-treating-chronic-kidney-disease-patients-with-paricalcitol-in-german-and-austrian-clinical-practice-top-study
#9
Nicholas Obermüller, Alexander R Rosenkranz, Hans-Walter Müller, Dennis Hidde, András Veres, Sabine Decker-Burgard, Isolde Weisz, Helmut Geiger
Paricalcitol is approved for prevention and therapy of secondary hyperparathyroidism (sHPT) in patients with chronic kidney disease (CKD), with only short-term data in clinical routine settings. A 12-month observational study was conducted in Germany and Austria (90 centers, 761 patients) from 2008 to 2013. Laboratory values, demographical, and clinical data were documented in 629 dialysis patients and 119 predialysis patients. In predialysis patients, median intact parathormone (iPTH) was 180.0 pg/mL (n = 105) at the start of the study, 115...
September 28, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28887037/cholecalciterol-cholesterol-emulsion-attenuates-experimental-autoimmune-myocarditis-in-mice-via-inhibition-of-the-pyroptosis-signaling-pathway
#10
COMPARATIVE STUDY
Ning Liu, Han Su, Yalin Zhang, Zuwang Liu, Juan Kong
1,25-dihydroxyvitamin D3 and its analog (paricalcitol) have beneficial effects on multiple systems and diseases, including myocarditis. However, the therapeutic effect of cholecalciterol cholesterol emulsion (CCE) on myocarditis and the role of pyroptosis in the progress of myocarditis have not been determined. The objective of this study was to investigate the effect of CCE on experimental autoimmune myocarditis and its underlying mechanisms. The ratio of heart weight to body weight was decreased after CCE treatment compared with vehicle-treated controls...
November 4, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28883900/corrigendum-to-paricalcitol-pretreatment-attenuates-renal-ischemia-reperfusion-injury-via-prostaglandin-e2-receptor-ep4-pathway
#11
Yu Ah Hong, Keum Jin Yang, So Young Jung, Ki Cheol Park, Hyunsu Choi, Jeong Min Oh, Sang Ju Lee, Yoon Kyung Chang, Cheol WheePark, Chul Woo Yang, Suk Young Kim, Hyeon Seok Hwang
[This corrects the article DOI: 10.1155/2017/5031926.].
2017: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/28873971/clinical-practice-recommendations-for-treatment-with-active-vitamin-d-analogues-in-children-with-chronic-kidney-disease-stages-2-5-and-on-dialysis
#12
Rukshana Shroff, Mandy Wan, Evi V Nagler, Sevcan Bakkaloglu, Mario Cozzolino, Justine Bacchetta, Alberto Edefonti, Constantinos J Stefanidis, Johan Vande Walle, Gema Ariceta, Günter Klaus, Dieter Haffner, Claus Peter Schmitt
In patients with chronic kidney disease (CKD), renal synthesis of active vitamin D [1,25-dihydroxyvitamin D (1,25(OH)2D)] declines and is associated with hypocalcaemia, secondary hyperparathyroidism and the spectrum of CKD-mineral and bone disorder (MBD). In advanced CKD, active vitamin D analogues, including alfacalcidol, calcitriol and paricalcitol, are routinely administered. There are few studies on the use of vitamin D analogues in children with CKD and on dialysis. It is difficult to define bone-specific outcomes that can guide treatment with active vitamin D analogues in children with CKD-MBD...
July 1, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28841848/comparative-efficacy-and-safety-of-paricalcitol-versus-vitamin-d-receptor-activators-for-dialysis-patients-with-secondary-hyperparathyroidism-a-meta-analysis-of-randomized-controlled-trials
#13
Yifeng Xie, Peiling Su, Yifan Sun, Hongsheng Zhang, Rong Zhao, Liang Li, Lanfen Meng
BACKGROUND: Secondary hyperparathyroidism (SHPT) is a severe complication for dialysis patients. Vitamin D receptor activators (VDRAs) are used to treat SHPT, but the comparative efficacy and safety between paricalcitol and other vitamin D receptor activators for management of SHPT in dialysis patients has been unproven. METHODS: We searched PubMed, Embase, and the Cochrane Library for the time period through June 2017 to identify randomized controlled trials that evaluated paricalcitol compared with other VDRAs for treatment of SHPT...
August 25, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28835982/effects-of-paricalcitol-on-cardiovascular-outcomes-and-renal-function-in-patients-with-chronic-kidney-disease-a-meta-analysis
#14
REVIEW
X Hu, J Shang, W Yuan, S Zhang, Y Jiang, B Zhao, Y Duan, J Xiao, Z Zhao
BACKGROUND: Paricalcitol, a selective activator of the vitamin D receptor (VDR), influences calcium and phosphorus homeostasis and bone metabolism. Whether paricalcitol reduces cardiovascular risk and protects renal function remains unclear. To systematically evaluate this in patients with chronic kidney disease (CKD), we conducted a meta-analysis of published randomized controlled trials (RCTs). METHODS: We searched MEDLINE, Embase, the Cochrane Library, and reference lists for RCTs comparing paricalcitol with placebo in stage 2-5 CKD (including pre-dialysis and renal replacement patients)...
August 23, 2017: Herz
https://www.readbyqxmd.com/read/28753620/treatment-combining-aliskiren-with-paricalcitol-is-effective-against-progressive-renal-tubulointerstitial-fibrosis-via-dual-blockade-of-intrarenal-renin
#15
Sungjin Chung, Soojeong Kim, Minyoung Kim, Eun Sil Koh, Seok Joon Shin, Cheol Whee Park, Yoon Sik Chang, Ho-Shik Kim
The aim of this study was to assess any potential additive effects of a treatment combining aliskiren with paricalcitol on reducing renal fibrosis. C57BL/6J mice were treated individually with aliskiren and/or paricalcitol until 7 days after initiation of unilateral ureteral obstruction (UUO).In obstructed kidneys of UUO mice, monotherapy with aliskiren or paricalcitol significantly attenuated interstitial fibrosis, collagen IV accumulation, and α-smooth muscle actin- and terminal deoxynucleotidyl transferase-mediated biotin nick end-labeling-positive cells...
2017: PloS One
https://www.readbyqxmd.com/read/28750928/paricalcitol-and-cinacalcet-have-disparate-actions%C3%A2-on-parathyroid-oxyphil-cell-content-in%C3%A2-patients-with-chronic-kidney-disease
#16
Cynthia Ritter, Brent Miller, Daniel W Coyne, Diptesh Gupta, Sijie Zheng, Alex J Brown, Eduardo Slatopolsky
The parathyroid oxyphil cell content increases in patients with chronic kidney disease (CKD), and even more in patients treated with the calcimimetic cinacalcet and/or calcitriol for hyperparathyroidism. Oxyphil cells have significantly more calcium-sensing receptors than chief cells, suggesting that the calcium-sensing receptor and calcimimetics are involved in the transdifferentiation of a chief cell to an oxyphil cell type. Here, we compared the effect of the vitamin D analog paricalcitol (a less calcemic analog of calcitriol) and/or cinacalcet on the oxyphil cell content in patients with CKD to further investigate the genesis of these cells...
November 2017: Kidney International
https://www.readbyqxmd.com/read/28737133/pretreatment-with-paricalcitol-attenuates-level-and-expression-of-matrix-metalloproteinases-in-a-rat-model-of-renal-ischemia-reperfusion-injury%C3%A2
#17
Sibel Ersan, Asli Celik, Mehmet Tanrisev, Isil Kose, Zahide Cavdar, Mehtat Unlu, Ayse Kocak, Cemre Ural, Banu Yilmaz, Timur Kose
BACKGROUND: Ischemia-reperfusion injury (IRI) is a leading cause of acute kidney injury (AKI). The inflammatory response that drives IRI involves upregulation of matrix metalloproteinases (MMPs), which results in proteolytic degradation of renal microvascular matrix. Evidence suggests a potential protective role of active vitamin D on ischemic injury by downregulating MMPs. In the present study, we aimed to determine the expression and level of MMP-2 and MMP-9 in renal IRI model and the potential beneficial effect of paricalcitol on both level and expression of MMPs and tubular injury caused by IRI...
November 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/28720647/in-situ-targeting-of-dendritic-cells-sets-tolerogenic-environment-and-ameliorates-cd4-t-cell-response-in-the-postischemic-liver
#18
Dominik Funken, Hellen Ishikawa-Ankerhold, Bernd Uhl, Maximilian Lerchenberger, Markus Rentsch, Doris Mayr, Steffen Massberg, Jens Werner, Andrej Khandoga
CD4(+) T cells recruited to the liver play a key role in the pathogenesis of ischemia/reperfusion (I/R) injury. The mechanism of their activation during alloantigen-independent I/R is not completely understood. We hypothesized that liver-resident dendritic cells (DCs) interact with CD4(+) T cells in the postischemic liver and that modulation of DCs or T-cell-DC interactions attenuates liver inflammation. In mice, warm hepatic I/R (90/120-240 min) was induced. Tolerogenic DCs were generated in situ by pretreatment of animals with the vitamin D analog paricalcitol...
July 18, 2017: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/28680822/paricalcitol-attenuates-lipopolysaccharide-induced-inflammation-and-apoptosis-in-proximal-tubular-cells-through-the-prostaglandin-e2-receptor-ep4
#19
Yu Ah Hong, Keum Jin Yang, So Young Jung, Yoon Kyung Chang, Cheol Whee Park, Chul Woo Yang, Suk Young Kim, Hyeon Seok Hwang
BACKGROUND: Vitamin D is considered to exert a protective effect on various renal diseases but its underlying molecular mechanism remains poorly understood. This study aimed to determine whether paricalcitol attenuates inflammation and apoptosis during lipopolysaccharide (LPS)-induced renal proximal tubular cell injury through the prostaglandin E2 (PGE2) receptor EP4. METHODS: Human renal tubular epithelial (HK-2) cells were pretreated with paricalcitol (2 ng/mL) for 1 hour and exposed to LPS (1 μg/mL)...
June 2017: Kidney Research and Clinical Practice
https://www.readbyqxmd.com/read/28680818/anti-inflammatory-and-anti-apoptotic-effects-of-paricalcitol-in-lipopolysaccharide-induced-renal-proximal-tubular-cell-injury
#20
EDITORIAL
Soo Wan Kim
No abstract text is available yet for this article.
June 2017: Kidney Research and Clinical Practice
keyword
keyword
8287
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"